Biomarker Discovery for Suicide Precision Circuit Therapeutics
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorMassachusetts General Hospital
About this trial
This is a prospective observational biomarker study assessing changes in clinical, behavioral, neuroimaging, and neurophysiological measurer following ketamine/esketamine or electroconvulsive therapy (ECT) in adults with suicidal thoughts or behaviors.
Eligibility criteria
Qualifiers
Adults aged 18 to 65 years
Diagnosis of a major depressive episode associated with Major Depressive Disorder or Bipolar Disorder
Presence of moderate to severe suicidal thoughts or behaviors, as determined by the Beck Scale for Suicide Ideation (BSSI)
Scheduled to receive an acute treatment course of electroconvulsive therapy (ECT), intravenous ketamine, or intranasal esketamine as part of routine clinical care
Disqualifiers
Neurological disorders, particularly conditions associated with known structural brain lesions
Inability to meet MRI safety requirements
Current alcohol dependence
Active symptoms of non-alcohol psychoactive substance withdrawal
Trial design
Treatments tested in this trial
- Not listed
Trial groups
60 Participants
are grouped into 2 trial groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov